Loperamide

Major

Loperamide Tazemetostat Tazverik Altered loperamide exposure, an increased risk of loperamide-related adverse reactions and reduced efficacy of loperamide Details Loperamide Tecovirimat An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Telaprevir An increased risk of QT interval prolongation, an increased risk of other ventricular arrhythmias, cardiac arrest, an increased lo... Details Loperamide Telavancin Vibativ An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Telithromycin An increased risk of QT interval prolongation, an increased risk of other ventricular arrhythmias, cardiac arrest, an increased lo... Details Loperamide Telmisartan Micardis Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Tepotinib Tepmetko Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Teriflunomide Aubagio Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Tetrabenazine Xenazine An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Tezacaftor Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Ticagrelor Brilinta An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Tolterodine Detrol An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Tolvaptan Jynarque An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Toremifene Fareston An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Trazodone Raldesy An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Treosulfan Grafapex Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Triclabendazole Egaten An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Trimethoprim Primsol An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Trimipramine An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Triptorelin An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Trofinetide Daybue Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Troleandomycin Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Tucatinib Tukysa An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Ulipristal Ella Increased loperamide exposure Details Loperamide Valbenazine Ingrezza Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Vandetanib Caprelsa Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Loperamide Vanzacaftor Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Vardenafil Levitra An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Velpatasvir Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Vemurafenib Zelboraf Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Loperamide Venetoclax Venclexta Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Loperamide Venlafaxine An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Vepdegestrant Veppanu An increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, ot... Details Loperamide Verapamil Calan An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Vibegron Gemtesa Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Vilanterol An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Vilazodone Viibryd Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Viloxazine Qelbree Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Vimseltinib Romvimza Increased risk of P-gp substrate exposure Details Loperamide Vinflunine An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details